Eye AI performs unexceptionally in clinical settings

Detecting diabetic retinopathy on eyeball imaging has been touted as one of medical AI’s most promising applications, as “the machine” has repeatedly equaled or bested humans at the task.

However, most of the action has taken place in research settings. A new study looking at the technology’s competence in real-world care presents some sobering findings.

Led by investigators at UW Medicine in Seattle, the study team compared the performance of seven different algorithms against that of experienced ophthalmologists.

The humans proved more accurate than six of the algorithms, and the seventh managed no better than a tie.

The project’s impact may be considerable thanks to its size, reach and ramifications. 

The patients were more than 23,000 veterans who were screened for diabetic retinopathy at VA centers in Washington State and Georgia. The algorithms came from four countries, and the retinal images numbered more than 311,000.

Further, if not properly diagnosed and treated, diabetic retinopathy can lead to serious vision problems, including blindness.

Noting that the algorithms yielded significant performance differences not only versus the physicians but also against one another, the authors conclude the results “argue for rigorous testing of all such algorithms on real-world data before clinical implementation.”

The study report is running in the January edition of Diabetes Care, which is published by the American Diabetes Association.

In coverage posted by UW Medicine’s news operation, lead study author Aaron Lee, MD, comments: “It’s alarming that some of these algorithms are not performing consistently since they are being used somewhere in the world.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.